TABLE 2.
Physician's choice of treatment received across all eligible lines of therapy in the RW cohort
| Treatments | Hierarchy a N (%) 336 (100%) | Received in any eligible line of therapy b N (%) 336 (100%) |
|---|---|---|
| Carfilzomib | 98 (29) | 98 (29) |
| Pomalidomide | 69 (21) | 97 (29) |
| Daratumumab | 28 (8) | 54 (16) |
| Ixazomib | 20 (6) | 29 (9) |
| Elotuzumab | 21 (6) | 43 (13) |
| Bortezomib | 30 (9) | 61 (18) |
| Lenalidomide | 7 (2) | 55 (16) |
| Panobinostat | 1 (0) | 4 (1) |
| Selinexor | 11 (3) | 17 (5) |
| Thalidomide, or melphalan, or cyclophosphamide c | 15 (4) | 83 (25) |
| Dexamethasone alone | 5 (1) | 5 (1) |
| Others d | 31 (9) | 64 (19) |
a
For each treatment, the number and percent represent the patients who received that treatment as a single‐agent therapy or in combination with any of the other treatments listed in the subsequent rows.
b
Received alone or in combination; therefore, the total adds to more than 100% as treatments from the same line of therapy can be counted more than once.
c
Any one received alone or in combination with either one of the three or other drugs.
d
“Others” included bendamustine, cisplatin, doxorubicin, etoposide, decitabine, fludarabine, ibrutinib, venetoclax, and clinical study drug.
Abbreviation: RW, real world.